SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biomatrix (BXM) Looking Great
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John McCarthy who wrote (307)1/1/1998 10:17:00 PM
From: tnsaf  Read Replies (1) of 569
 
<<In early 1997 the FDA became aware of this, and in the course
of 5 weeks - FROM A STANDING STOP - BMY filed with the FDA
to have TAXOL reviewed under the Orphan Drug Statutes AND
the FDA agreed to review their request. This was in June.
In August the FDA ruled that TAXOL ($1 bil. drug) was indeed
an ORPHAN DRUG.>>
I thought drugs were orphaned for specific indications, such as Taxol for KS but not ovarian cancer.

Jason
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News